ES2297203T3 - Pirazolopiridinas como inhibidores de quinasas dependientes de ciclina. - Google Patents

Pirazolopiridinas como inhibidores de quinasas dependientes de ciclina. Download PDF

Info

Publication number
ES2297203T3
ES2297203T3 ES03752559T ES03752559T ES2297203T3 ES 2297203 T3 ES2297203 T3 ES 2297203T3 ES 03752559 T ES03752559 T ES 03752559T ES 03752559 T ES03752559 T ES 03752559T ES 2297203 T3 ES2297203 T3 ES 2297203T3
Authority
ES
Spain
Prior art keywords
alkyl
aryl
group
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03752559T
Other languages
English (en)
Spanish (es)
Inventor
Michael P. Dwyer
Timothy J. Guzi
Kamil Paruch
Ronald J. Doll
Kartik M. Keertikar
Viyyoor M. Girijavallabhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2297203T3 publication Critical patent/ES2297203T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES03752559T 2002-09-19 2003-09-17 Pirazolopiridinas como inhibidores de quinasas dependientes de ciclina. Expired - Lifetime ES2297203T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41213802P 2002-09-19 2002-09-19
US412138P 2002-09-19

Publications (1)

Publication Number Publication Date
ES2297203T3 true ES2297203T3 (es) 2008-05-01

Family

ID=32030811

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03752559T Expired - Lifetime ES2297203T3 (es) 2002-09-19 2003-09-17 Pirazolopiridinas como inhibidores de quinasas dependientes de ciclina.

Country Status (18)

Country Link
US (1) US7151104B2 (enExample)
EP (1) EP1539750B1 (enExample)
JP (1) JP4845380B2 (enExample)
KR (1) KR20050072090A (enExample)
CN (1) CN100475812C (enExample)
AR (1) AR041292A1 (enExample)
AT (1) ATE382048T1 (enExample)
AU (1) AU2003270846B2 (enExample)
CA (1) CA2499593C (enExample)
DE (1) DE60318321T2 (enExample)
ES (1) ES2297203T3 (enExample)
IL (1) IL167432A (enExample)
MX (1) MXPA05003059A (enExample)
MY (1) MY136840A (enExample)
NZ (1) NZ538595A (enExample)
TW (1) TWI283243B (enExample)
WO (1) WO2004026872A1 (enExample)
ZA (1) ZA200502271B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ES2403558T3 (es) * 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
KR20070108270A (ko) * 2005-02-28 2007-11-08 에자이 알앤드디 매니지먼트 가부시키가이샤 술폰아미드 화합물의 신규 병용
WO2006090931A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の抗癌剤との新規併用
US7304074B2 (en) 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
WO2006109867A1 (ja) * 2005-04-07 2006-10-19 Teijin Pharma Limited ピラゾロ［１，５-ａ］ピリジン誘導体またはその医学上許容される塩
US7417053B2 (en) 2005-04-07 2008-08-26 Teijin Pharma Limited Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
WO2007032936A2 (en) 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
WO2008066789A2 (en) * 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
KR20090031122A (ko) * 2007-09-21 2009-03-25 주식회사 중외제약 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2016160617A2 (en) * 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017087409A1 (en) 2015-11-18 2017-05-26 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
MX390117B (es) * 2016-09-07 2025-03-20 Haihe Biopharma Co Ltd Compuesto de anillo aromatico de pirido de cinco elementos, metodo de preparacion y uso del mismo.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69627195T2 (de) 1995-11-01 2004-01-29 Novartis Ag Purinderivate und verfahren zu ihrer herstellung
EP1043998B1 (en) 1997-12-13 2007-03-07 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDANT KINASE INHIBITORS
SE9802794D0 (sv) * 1998-08-21 1998-08-21 Astra Ab New compounds
FR2801308B1 (fr) * 1999-11-19 2003-05-09 Oreal COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES
WO2001056607A1 (en) * 2000-02-03 2001-08-09 Eisai Co., Ltd. Integrin expression inhibitors
AU2002225096B8 (en) * 2000-12-20 2006-07-27 Ipsen Pharma S.A.S. Cyclin-dependent kinase (CDK) and glycogen synthase kinase-3 (GSK-3) inhibitors
IL157461A0 (en) * 2001-03-08 2004-03-28 Astrazeneca Ab Astrazeneca Ab Use of carboxamido imidazo [1,2] pyridine deivatives in the preparation of medicaments for treating or preventing gastric ulcer
CN1202896C (zh) * 2002-02-07 2005-05-25 北京燕化高新技术股份有限公司 空气分离时纯化空气的方法

Also Published As

Publication number Publication date
NZ538595A (en) 2006-04-28
AR041292A1 (es) 2005-05-11
ATE382048T1 (de) 2008-01-15
EP1539750B1 (en) 2007-12-26
CN100475812C (zh) 2009-04-08
ZA200502271B (en) 2005-09-19
TW200409775A (en) 2004-06-16
CN1681816A (zh) 2005-10-12
JP4845380B2 (ja) 2011-12-28
IL167432A (en) 2010-05-17
EP1539750A1 (en) 2005-06-15
WO2004026872A1 (en) 2004-04-01
JP2006503060A (ja) 2006-01-26
AU2003270846A1 (en) 2004-04-08
US7151104B2 (en) 2006-12-19
TWI283243B (en) 2007-07-01
MY136840A (en) 2008-11-28
CA2499593C (en) 2011-08-16
DE60318321T2 (de) 2008-12-11
HK1071758A1 (en) 2005-07-29
AU2003270846B2 (en) 2006-11-23
KR20050072090A (ko) 2005-07-08
US20040097516A1 (en) 2004-05-20
MXPA05003059A (es) 2005-05-27
CA2499593A1 (en) 2004-04-01
DE60318321D1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
ES2283868T3 (es) Compuestos pirazol(1,5-a) pirimidina como inhibidores de quinasa dependiente de ciclina.
ES2293015T3 (es) Imidazopirazinas como inhibidores de cinasas dependientes de ciclinas.
ES2285164T3 (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
JP4845379B2 (ja) サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
AU2003275031B2 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
ES2345631T3 (es) Pirazolopirimidinas como inhibidores de quinasa dependiente de ciclina para el tratamiento del cancer.
ES2291665T3 (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
EP1720883B1 (en) Pyrazolotriazines as kinase inhibitors
ES2297203T3 (es) Pirazolopiridinas como inhibidores de quinasas dependientes de ciclina.
ES2349476T3 (es) Nuevos derivados de 4-ciano, 4-amino y 4-aminometilo de compuestos de pirazolo[1,5-a]piridinas, pirazolo[1,5-c]pirimidinas y 2h-indazol y derivados de 5-ciano, 5-amino y 5-aminometilo de compuestos de imidazo[1,2-a]piridinas e imidazo[1,5-a]pirazinas, como inhibidores de cinasa dependiente de ciclina.
AU2007200401A1 (en) Imidazopyrazines as cyclin dependent kinase inhibitors
HK1072056B (en) Imidazopyrazines as cyclin dependent kinase inhibitors
HK1112229B (en) Novel 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2h-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines compounds as cyclin dependent kinase inhi